Europe Non Invasive Prenatal Testing Market Size & Outlook
- Clinical Diagnostics
- Genetic Testing
- Non Invasive Prenatal Testing Market Outlook
- Genetic Testing
Global Market
Related Markets
Ask a question about the non invasive prenatal testing market
Europe non invasive prenatal testing market highlights
- The Europe non invasive prenatal testing market generated a revenue of USD 1,351.2 million in 2023.
- The market is expected to grow at a CAGR of 9.8% from 2024 to 2030.
- In terms of segment, 13-24 weeks was the largest revenue generating gestation period in 2023.
- 0-12 weeks is the most lucrative gestation period segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 1,351.2 million |
| Market revenue in 2030 | USD 2,567.8 million |
| Growth rate | 9.8% (CAGR from 2024 to 2030) |
| Largest segment | 13-24 weeks |
| Fastest growing segment | 0-12 weeks |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
| Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
Other key industry trends
- In terms of revenue, Europe region accounted for 32.1% of the global non invasive prenatal testing market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,666.8 million by 2030.
Initiatives to improve pricing policies and innovation in this field may revive the already matured Europe non-invasive prenatal testing market, which may boost the market over the forecast period. The percentage of women who undergo NIPT in Germany is more than the European average, which is more than 50%.
Moreover, liberal regulations in several countries for aneuploidy screening are expected to drive market growth. Tissue matching through HLA typing is also allowed in France. However, sex selection of embryos is allowed for medical purposes only.
In addition, Assisted Reproductive Technology (ART) is allowed to be performed only for heterosexual couples if they are married for at least two years before the procedure is performed. Moreover, since NIPT was introduced in the region in 2011, it has gained popularity quickly and companies are forming partnerships and collaborations to explore the market.
No credit card required*
Publish Date: Dec 15, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non Invasive Prenatal Testing Market Scope
Non Invasive Prenatal Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| Natera Inc | View profile | 3,293 | 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 | www.natera.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Centogene NV Ordinary Shares | View profile | 493 | Am Strande 7, Rostock, MV, Germany, 18055 | www.centogene.com |
| Biora Therapeutics | View profile | 51-100 | Carlsbad, California, United States, North America | www.bioratherapeutics.com/ |
Europe Non Invasive Prenatal Testing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Non Invasive Prenatal Testing Market Outlook will help companies and investors design strategic landscapes.
13-24 Weeks was the largest segment with a revenue share of 56.35% in 2023.
Horizon Databook has segmented the Europe non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
Initiatives to improve pricing policies and innovation in this field may revive the already matured Europe non-invasive prenatal testing market, which may boost the market over the forecast period. The percentage of women who undergo NIPT in Germany is more than the European average, which is more than 50%.
Moreover, liberal regulations in several countries for aneuploidy screening are expected to drive market growth. Tissue matching through HLA typing is also allowed in France. However, sex selection of embryos is allowed for medical purposes only.
In addition, Assisted Reproductive Technology (ART) is allowed to be performed only for heterosexual couples if they are married for at least two years before the procedure is performed. Moreover, since NIPT was introduced in the region in 2011, it has gained popularity quickly and companies are forming partnerships and collaborations to explore the market.
- Europe Non Invasive Prenatal Testing Market Gestation Period Outlook (Revenue, USD Million , 2018-2030)
- 0-12 weeks
- 13-24 weeks
- 25-36 weeks
- Europe Non Invasive Prenatal Testing Market Risk Outlook (Revenue, USD Million , 2018-2030)
- High & Average Risk
- Low Risk
- Europe Non Invasive Prenatal Testing Market Method Outlook (Revenue, USD Million , 2018-2030)
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
- Europe Non Invasive Prenatal Testing Market Technology Outlook (Revenue, USD Million , 2018-2030)
- NGS
- Array Technology
- PCR
- Others
- Europe Non Invasive Prenatal Testing Market Product Outlook (Revenue, USD Million , 2018-2030)
- Consumables & Reagents
- Instruments
- Europe Non Invasive Prenatal Testing Market Application Outlook (Revenue, USD Million , 2018-2030)
- Trisomy
- Microdeletion Syndrome
- Other Applications
- Europe Non Invasive Prenatal Testing Market End-use Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Clinics
- Diagnostic Laboratories
Reasons to subscribe to Non Invasive Prenatal Testing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Non Invasive Prenatal Testing Market Outlook databook
- Our clientele includes a mix of Non Invasive Prenatal Testing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Non Invasive Prenatal Testing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Non Invasive Prenatal Testing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Europe Non Invasive Prenatal Testing Market, 2018-2030 (US$M)
Europe non invasive prenatal testing market statistics, by gestation period, 2018-2030 (US$M)
